NCT03297697

Minimal Residual Disease in Peripheral T-cell Lymphoma

A Multi-Institutional Prospective Cohort Study of Minimal Residual Disease in Peripheral T-cell Lymphoma

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 44 (actual)
• Sponsor: Washington University School of Medicine · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

As T-cell receptor sequencing by LymphoTrack is an assay with high sensitivity that can be performed in peripheral blood, the investigators wish to evaluate the ability of this assay to predict which patients are at higher risk of relapse after initial therapy for peripheral T-cell lymphomas which is being given for curative intent. Additionally, as more is known about the ability of dynamic monitoring of cfDNA in B-cell lymphomas to predict relapse, the investigators wish to explore the use of this technology in T-cell lymphomas.

Conditions

• Peripheral T Cell Lymphoma

Interventions

Type	Name	Description
PROCEDURE	Tumor biopsy	Biopsy specimen can be from bone marrow, blood, or lymph node. This specimen should have a high disease load
PROCEDURE	Peripheral blood draw	-Baseline, C1D1, C1D8, C1D15, C2D1, C3D1, C4D1, C5D1, C6D1, end of treatment, 3 month follow-up (optional), 6 month follow-up, 9 month follow-up (optional), 12 month follow-up, 15 month follow-up (optional), 18 month follow-up, 21 month follow-up (optional), 24 month follow-up, and at relapse
PROCEDURE	Lymphotrack TCR clonality assay	-Assay with high sensitivity that can be performed with peripheral blood

Timeline

• Start date: 2017-07-31
• Primary completion: 2023-11-30
• Completion: 2023-11-30
• First posted: 2017-09-29
• Last updated: 2024-05-16

Locations

3 sites across 1 country: United States